Clinical Trial Update: A Study to Evaluate 4-year Antibody Persistence and Booster Response Following MenABCWY Vaccination in Healthy Adolescents and Young Adults Who Previously Participated in Studies V102_02 (NCT01210885) and V102_02E1 (NCT01367158) [Phase 2]

View source ↗

Summary

Phase 2 trial update assessing 4-year antibody persistence and booster response after MenABCWY vaccination in adolescents/young adults who previously participat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Meningococcal Disease

Drugs mentioned

• MenABCWY

Snippet

Sponsor: GlaxoSmithKline | Conditions: Meningococcal Disease, Infections, Meningococcal | Phase 2 | Status: COMPLETED | Results posted: 2020-07-09